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Abstract
Background: Lung adenocarcinoma (LAD) is considered to be a highly aggressive disease with heterogeneous
prognosis and the molecular mechanisms underlying tumor progression remain elusive. Growing evidence
demonstrates that the dysregulation of microRNAs (miRNAs) plays an important role in various tumor processes.
The aim of this study is to discover prognostic miRNA and investigate its role involved in progression of LAD.
Methods: Prognosis related miRNA was detected by miRNA microarray using formalin-fixed paraffin-embedded
(FFPE) specimens from 87 patients with IIIA-N2 LAD. The cell proliferation was evaluated by Cell Titer 96 AQueous
One Solution Cell Proliferation Assay (MTS), and the migration/invasion was evaluated by transwell assay. The
bioinformatics methods and luciferase reporter assay were applied to detect the relationship between miRNA and
its target. The mRNA and protein levels of miRNA target were determined by quantitative real time polymerase
chain reaction (qRT-PCR) analysis, western blot and enzyme-linked immunosorbent assay (ELISA). Changes of
angiogenesis induced by miRNA was evaluated by human umbilical vein endothelial cell (HUVEC) tube formation
assay. Immunohistochemistry (IHC) analysis was performed in FFPE specimens of patients to evaluate the correlation
between miR-29c with microvessel density (MVD) and vascular endothelial growth factor A (VEGFA) expression.
Results: MiR-29c expression downregulation was significantly associated with unfavorable prognosis in IIIA-N2 LAD.
MiR-29c inhibited cell proliferation, migration and invasion in cell lines. Integrated analysis revealed that VEGFA
was a direct target of miR-29c. MiR-29c reduced the capability of tumor cells to promote HUVEC tube formation.
The compromised cell proliferation, migration/invasion and angiogenesis induced by miR-29c mimic transfection
were reversed by transfection of VEGFA expression plasmid. Furthermore, the correlation of miR-29c with MVD
and VEGFA was confirmed in patients’ samples.
Conclusions: MiR-29c acts as a tumor suppressor by targeting VEGFA and may represent a promising prognostic
biomarker as well as a potential therapeutic target for LAD.
Keywords: Lung adenocarcinoma, MiR-29c, VEGFA
* Correspondence: wlhwq@yahoo.com
†Equal contributors
1Department of Radiation Oncology, National Cancer Center/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing 100021, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. Molecular Cancer  (2017) 16:50 
DOI 10.1186/s12943-017-0620-0
Background
Lung cancer is the leading cause of cancer-related deaths
worldwide [1]. Non-small-cell lung cancer (NSCLC) ac-
counts for 85% of all lung cancer cases and approxi-
mately half of NSCLC are lung adenocarcinoma (LAD)
[2]. With high invasiveness and early metastasis, LAD
often presents with locally advanced or metastatic disease
at prognosis [3]. Furthermore, stage IIIA-N2 LAD pre-
sents substantial heterogeneity ranging from resectable
microscopic lymph node disease to unresectable, bulky
nodal metastases [4], with 5-year overall survival (OS)
ranging from 13 to 58.3%[5–7]. The current tumor-node-
metastasis staging system is inadequate to explain the
large variability in disease outcome for stage IIIA-N2
LAD. Moreover, despite treatment efficacy improvement
attributable to the target-specific inhibitors to epidermal
growth factor receptor (EGFR) or anaplastic lymphoma
kinase (ALK), only 15–30% of LAD harbor sensitizing
mutation in EGFR or ALK gene rearrangement [8]. There-
fore, discovery of novel precise prognostic biomarkers is
warranted and a better understanding of molecular mech-
anisms underlying tumor progression may facilitate the
development of effective therapeutic strategies for LAD.
MicroRNAs (miRNAs) are a group of short, noncoding
RNAs that negatively regulate gene expression post-
transcriptionally by binding to the 3’-untranslated regions
(3’-UTR) of their target gene mRNAs, thereby controling
a variety of cellular functions such as proliferation, dif-
ferentiation and apoptosis [9]. Emerging evidence indi-
cates that aberrant expression of miRNAs is closely
associated with tumorigenesis and cancer progression
via the regulation of key oncogenes or tumor suppres-
sors [10]. Therefore, miRNA may have great potential
as a prognostic indicator and therapeutic target [11]. It
is well established that miRNA may perform different
functions through distinct pathways in a way that de-
pends on the context or tissue specificity [12]. A num-
ber of investigations have demonstrated that aberrant
miRNA expression contributes to NSCLC progression,
such as miR-1, let-7 and miR-21 [13–15]. However,
miRNAs identified in the regulation of LAD progres-
sion are limited [16, 17].
In this report, we first performed miRNA microarray to
survey expression of 1105 known miRNAs in formalin-
fixed paraffin-embedded (FFPE) specimens of 87 patients
and discovered that downregulation of miR-29c to be
significantly related to poor prognosis of patients with
IIIA-N2 LAD. We further validated the tumour sup-
pressive role of miR-29c showing evidence that miR-
29c inhibits proliferation, migration and invasion in
LAD cell lines. We also confirmed that vascular endo-
thelial growth factor A (VEGFA) is a novel, downstream
gene target of miR-29c which played an essential role in
angiogenesis in vitro.
Methods
Patients and tissue specimens
The FFPE specimens of 87 cases with pathologically
confirmed IIIA-N2 LAD and available clinical informa-
tion as well as follow-up information were obtained at
the Cancer Hospital, Chinese Academy of Medical
Sciences from 2003 to 2005. All the patients underwent
radical surgical resection. Patients who underwent
preoperative radiotherapy and chemotherapy were ex-
cluded. Written informed consent was obtained by all
patients and the study was approved by the Institutional
Review Boards of Cancer Hospital, Chinese Academy of
Medical Sciences.
MiRNAs microarray and quantitative real time polymerase
chain reaction (qRT-PCR) analysis
Total RNA was extracted using Trizol reagent, and
miRNAs from both cultured cells and FFPE specimens
were obtained using mirVana miRNA Isolation Kit
(Ambion, USA). Affymetrix GeneChip miRNA 2.0 Array
including probes for 1105 mature human miRNA se-
quences was performed by a service provider (CapitalBio,
Beijing, China).
The expression level of miR-29c was quantified by the
stem-loop qRT-PCR method. The cDNA was prepared
from total RNA (2 ug) with the miR-29c stem-loop RT
primers or U6 RT primers (RiboBio, China) by using the
First-Strand cDNA Synthesis kit (Promega, USA). U6
small nuclear RNA was used as an internal control for
miR-29c. For quantification of VEGFA, the RNA was re-
versely transcribed into cDNA with the First-Strand
cDNA Synthesis kit (Promega, USA) using oligo primers.
Primer sequences of VEGFA were as follows: forward:
5’-CGCAGCTACTGCCATCCAAT-3’; reverse: 5’-GTGA
GGTTTGATCCGCATAATCT-3’. β-actin mRNA was
used as an internal control for VEGFA transcript. Then,
the qRT-PCR was conducted using Light Cycler DNA
Master SYBR Green I Mix (Roche, Switzerland) on an
ABI Prizm 7300 Sequence Detection System. The miR-
29c and VEGFA mRNA were quantified with the 2-ΔΔCt
method and normalized with the level of the internal
control, respectively.
Cell culture and transfection
Human LAD cell lines (A549, NCI-H1299, NCI-H157,
GLC-82, and Anip973) were cultured in RPMI-1640
(Gibco, USA) supplemented with 10% fetal bovine
serum (FBS). HUVECs were maintained in DMEM
(Gibco, USA) supplemented with 10% FBS. All cells
were maintained at 37 °C in a humidified incubator
under 5% CO2 condition. The miR-29c mimic, inhibi-
tor, mimic negative control (NC) and inhibitor NC
were purchased from RiboBio (Guangzhou, China). The
corresponding sequences were as follows: miR-29c
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mimic: UAGCACCAUUUGAAAUCGGUUA; miR-29c
inhibitor: UAACCGAUUUCAAAUGGUGCUA; mimic
NC: UUUGUACUACACAAAAGUACUG; inhibitor NC:
UUUGUACUACACAAAAGUACUG. The miRNA trans-
fection was conducted at a concentration of 50 nM using
Lipofectamine 2000 (Invitrogen, USA) following manufac-
turer’s instructions.
Bioinformatics methods
The potential target genes of miR-29c were predicted using
several online programs with databases of different algo-
rithms, including TargetScan (http://www.targetscan.org/),
MICRORNA.ORG (http://www.microrna.org/) and MIRDB
(http://mirdb.org/).
Plasmid constructs and luciferase reporter assay
VEGFA expression plasmid pEGFP-N1-VEGFA was
generated by cloning open reading frame (ORF) of
VEGFA into pEGFP-N1 vector (Generay, China). To
construct the VEGFA-3’-UTR-wildtype (WT) plasmid,
the 3’-UTR of human VEGFA mRNA including pre-
dicted miR-29c target binding sequences was amplified
by PCR and cloned into the pGV126 vector (Genechem,
China). The VEGFA 3’-UTR-mutant (MUT) plasmid
harbored a substation of 12 nucleotides within the
binding region of the VEGFA 3’-UTR. In each construct,
the 3’-UTR fragment was inserted downstream of the
firefly luciferase gene region. A549 cells grown in a 12-
well plate were co-transfected with 400 ng of each
reporter construct per 20 ng internal control renilla lu-
ciferase plasmid (pRL-SV40) and 100 nM of mimic or
mimic-NC using Lipofectamie 2000 (Invitrogen, USA).
Cells were harvested 48 h after transfection and assayed
with the Dual Luciferase Assay kit (Promega, USA) using
Synergy H1 hybrid reader (Biotek, USA). Luciferase activity
was normalized to the renilla luciferase activity.
Cell proliferation, migration and invasion assays
The proliferation of the transfected cells was evaluated
by Cell Titer 96 AQueous One Solution Cell Proliferation
Assay (MTS) (Promega, USA). 2000 transfected cells were
seeded in a 96-well plate. After 24 h, 48 h and 72 h, 100 μl
5% MTS was added in a 96-well plate and incubated for
2 h before reading at a wavelength of 490 nm by a micro-
plate reader (Bio-Rad, USA).
The migration and invasion of transfected cells were
evaluated by transwell assay. In the migration assay, 5 ×
104 (A549) or 10 × 104 (Anip973) cells were cultured in
200 μl serum-free media in the upper chamber of a non-
coated transwell 8 μm insert (Costar, USA). For the inva-
sion assay, the upper chamber of the transwell insert was
pre-coated with 100 μl of 2% matrigel (BD Biosciences,
USA). The lower chamber was loaded with 600 μl RPMI-
1640 containing 20% FBS. After 8–12 h, cells that did not
migrate or invade were removed with a cotton swab. The
migrated cells were fixed in methanol for 10 min and
stained with crystal violet for 5 min. Cells in 10 random
microscopic fields (×100 magnification) for each insert
were counted.
Preparation of tumor conditioned medium (TCM)
A549 cells transfected with miR-29c mimic or mimic-
NC and Anip973 cells transfected with miR-29c inhibitor
or inhibitor-NC were cultured in a 6-well plate. 48 h after
transfection, the medium was removed. Cells were washed
with phosphate-buffered saline (PBS) three times, and then
cultured in media free of serum for 24 h. TCM was col-
lected after centrifugation at 12,000 g for 10 min at 4 °C
and then stored at −80 °C until used.
Enzyme-linked immunosorbent assay (ELISA)
The levels of VEGFA in TCM were detected by ELISA
kits (R&D Systems, USA) according to the manufac-
turer’s instruction. TCM was diluted with the sample di-
lution buffer with a ratio of 1:1. Standard curves were
created using purified VEGFA and the CurveExpert 1.3
software program.
Western blot
Cells were lysed using lysis buffer (1% NP-40 supple-
mented with a complete protease inhibitor tablet (Sigma,
USA)) on ice. 25 μg protein extractions were separated
by a 10% SDS-PAGE gel and transferred to polyvinylidene
difluoride (PVDF) membranes (Millipore, USA). After
blocking with 3% bovine serum albumin (BSA) for 1 h,
the membranes were then incubated with primary anti-
bodies overnight at 4 °C: a rabbit polyclonal antibody
against VEGFA (1:500, Proteintech, China) and a mouse
monoclonal antibody for β-actin (1:5000, Santa Cruz,
USA). Afterwards, the membranes were incubated with ei-
ther anti-rabbit or anti-mouse HRP-conjugated secondary
antibody (1:3000 or 1:2000, Sigma–Aldrich, Australia) for
1 h. After incubation with the chemiluminescence sub-
strate, photographs were taken by ImageReader LAS-4000
(Fujifilm, Japan) and analyzed by Image-Pro Plus 6.0
software.
HUVEC tube formation assay
HUVECs (8 × 105) were suspended in the mixture of
TCM (300 ul) and DMEM (300 ul) with 10% FBS and
seeded on a 24-well plate coated with matrigel (300 ul/well,
BD Biosciences). After 6 h of incubation at 37 °C, tube
formation was observed and photographed with a
computer-assisted inverted microscope (Nikon). Ten
random fields per sample were photographed at × 100
magnification. The number of branch points of the
connected tubes was counted and compared between
different groups.
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Immunohistochemistry (IHC) analysis
IHC of VEGFA (1:100; Santa Cruz, USA) and CD31
(1:100; ZSGB-BIO, China) was performed in FFPE speci-
mens and visualized by diaminobenzidine (DAB). For
VEGFA, the intensity of staining (0, no staining; 1, weakly
stained; 2, moderately stained; 3, strongly stained) were
assessed by an experienced pathologist and the percentage
of positive cells was noted. The microvessel density
(MVD) was evaluated by CD31 immunohistochemistry
staining. The entire section was scanned at low magnifica-
tion (100×) to identify four hot spots. MVD was calculated
as the average count of microvessel in the four hot spots
at high magnification (400×).
Statistical analysis
Statistical analyses were performed with SPSS version
19.0 or GraphPad Prism version 6.0. Pearson χ2 test was
used to compare the baseline characteristics. Overall
survival (OS) was defined as the time to death or last
follow-up from the date of diagnosis. Disease-free sur-
vival (DFS) was defined as the time to progression or last
follow up or death from the date of diagnosis. Local re-
currence disease free survival (LRDFS) was defined as
the time to recurrence in the mediastinum, hilum and
supraclavicular fossa or last follow-up from the date of
diagnosis. Distant metastasis free survival (DMFS) was
defined as the time to any recurrence occurring in
contralateral lung, brain, bone or other locations or last
follow-up from the date of diagnosis. Using the median
level of miRNAs as cutoff value, the sample group was
classified as high expression group and low expression
group. Survival analysis was performed using the
Kaplan-Meier method and log-rank test. Univariate and
multivariate analyses by use of Cox-proportional hazards
model were performed to evaluate potential prognostic
factors for OS. For in vitro experiment, difference
between groups were analyzed using the Student’s t-test
(two-tailed). The Spearman’s correlation test was used
to examine correlation between miR-29c expression
with MVD and VEGFA expression. Data was presented
as the mean ± SD. A statistically significant difference
was defined as p < 0.05.
Results
Downregulation of miR-29c confers poor prognosis in
IIIA-N2 LAD
To investigate miRNAs’ prognostic role in IIIA-N2 LAD,
we first evaluated 1105 known miRNAs’ expression in
FFPE specimens using microarray assay from 87 cases
with IIIA-N2 LAD who received curative operation as
primary treatment in the Cancer Hospital, Chinese
Academy of Medical Sciences from 2003 to 2005. Using
the median miRNA expression as a cutoff, downregulation
of miR-29c was found to be an unfavorable prognostic
factor in IIIA-N2 LAD. As shown in Table 1, the
clinical characteristics were comparable between the
low miR-29c expression group and the high miR-29c
expression group.
The median OS and 5-year OS for all patients were
24 months and 26.9%, respectively. Patients in the high
expression group achieved significant survival prolonga-
tion compared with those in the low expression group
(median OS, 68.9 months vs. 25.1 months; 5-year OS,
58.1% vs. 6.8%; p < 0.001; Fig. 1a). The median DFS and
5-year DFS for the high expression group (27.5 months
and 27.9%) were also superior to those for the low ex-
pression group (10.1 months and 2.3%) (p < 0.001;
Fig. 1b), which was consistent with the OS results. The
5-year LRDFS were 62.4% in the high expression group
and 43.5% in the low expression group (p = 0.044;








< 60 y 27 (61.4%) 20 (46.5%)
≥ 60 y 17 (38.6%) 23 (53.3%)
Sex 0.458
Male 27 (61.4%) 23 (53.5%)




0 21 (47.7%) 19 (44.2%)
1 23 (52.3%) 24 (55.8%)
Weight loss 1.000
≤ 5% 42 (95.5%) 41 (95.3%)
> 5% 2 (4.5%) 2 (4.7%)
Smoking status 0.137
Smokers 19 (43.2%) 12 (27.9%)
Nonsmokers 25 (56.8%) 31 (72.1%)
Tumor stage 0.324
1 3 (6.8%) 7 (16.3%)
2 32 (72.7%) 30 (69.8%)




Yes 40 (90.9%) 36 (83.7%)




Yes 12 (27.3%) 6 (14.0%)
No 32 (72.7%) 37 (86.0%)
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Fig. 1c). The 5-year DMFS were 28.9% in the high ex-
pression group and 6.0% in the low expression group
(p = 0.002; Fig. 1d).
The results of the univariate and multivariate ana-
lyses of potential prognostic factors for OS are shown
in Table 2. Univariate analysis revealed that tumor
stage (p = 0.005), number of N2 station (p = 0.029) and
miR-29c expression (p < 0.001) were predictors for poor
OS. In the multivariate analysis, advanced tumor stage
(p = 0.033) and downregulation of miR-29c (p < 0.001)
were significantly correlated with unfavorable OS.
These results reveal that reduced miR-29c expression
is associated with unfavorable outcome of IIIA-N2
LAD.
MiR-29c inhibits cell proliferation, migration and invasion
in vitro
Five LAD cell lines were used to evaluate the expression
levels of miR-29c by qRT-PCR. As shown in Fig. 2a, the
expression level in the Anip973 cells was significantly
higher than that in the other four cell types (A549, NCI-
H1299, NCI-H157 and GLC-82) which expressed miR-
29c at low levels similarly. We selected A549 cells for
miR-29c mimic transfection and Anip973 cells for miR-29c
inhibitor transfection, respectively. As shown in Fig. 2b,
the miR-29c expression levels were increased by miR-
29c mimic in A549 cells and decreased by miR-29c in-
hibitor in Anip973 cells, respectively. Restoration of
miR-29c expression in A549 cells resulted in decreased
cell proliferation, whereas inhibition of miR-29c expres-
sion in Anip973 cells significantly increased cell prolife-
ration compared with the negative controls (Fig. 2c).
The migration and invasion capabilities were increased
in Anip973 cells treated with miR-29c inhibitor. Con-
versely, both capabilities were decreased by miR-29c
mimic in 549 cells (Fig. 2d). These results suggest that
miR-29c inhibits cell proliferation, migration and inva-
sion in vitro.
VEGFA is a direct target of miR-29c
To further investigate the mechanisms responsible for
the tumor-suppressive abilities of miR-29c, we searched
TargetScan, MICRORNA.ORG and MIRDB and verified
that VEGFA is a potential target of miR-29c. To con-
firm whether VEGFA was direct target of miR-29c, the
wildtype or mutant 3’-UTR of VEGFA was inserted into
the downstream of a firefly luciferase reporter gene to
create VEGFA 3’-UTR-WT and VEGFA 3’-UTR-MUT
Fig. 1 Comparison of survival between the low expression and high expression groups. a overall survival (OS), b disease-free survival (DFS), c local
regional disease free survival (LRDFS) and d distant metastasis free survival (DMFS)
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(Fig. 3a). Each firefly luciferase vector and renilla lucif-
erase vector (pRL-SV40) was cotransfected with mimic
or mimic-NC into A549 cells. The luciferase activity
was quantified and compared. As shown in Fig. 3b, the
luciferase activity of VEGFA 3’-UTR-WT but not the
mutant VEGFA reporter was reduced approximately
50% by miR-29c mimic compared to the mimic-NC,
suggesting that miR-29c could bind to the 3’-UTR of
VEGFA directly. Then we evaluated whether miR-29c
could regulate VEGFA at both mRNA and protein
levels (Fig. 3c, d and e). qRT-PCR analysis indicated
that overexpression of miR-29c in A549 cells resulted
in down-regulation of VEGFA mRNA compared with
control. TCM was collected from wells with A549 cells
transfected with miR-29c mimic or mimic-NC and
Anip973 cells transfected with miR-29c inhibitor or
inhibitor-NC. ELISA and western blot analysis revealed
that both secreted VEGFA in TCM and intracellular
VEGFA protein expression were reduced in miR-29c
mimic transfected A549 cells. Furthermore, inhibition
of miR-29c in Anip973 cells led to increased expression
of VEGFA mRNA and protein. It is concluded that
miR-29c represses VEGFA expression at both mRNA
and protein levels by directly targeting to its 3’-UTR.
Table 2 Results of the univariate and multivariate analyses of prognostic factors for OS
Univariate analysis Multivariate analysis
Characteristic MST (mos) 5-y OS (%) p-value HR 95% CI p-value
Age 0.394
< 60 y 31.3 29.8








≤ 5% 37.9 32.5




Tumor stage 0.005 0.033
1 43.8 50.0 0.456 0.167–1.248 0.126
2 40.7 35.4 0.441 0.237–0.818 0.009
3 15.9 6.7









MiR-29c expression <0.001 3.694 2.106–6.479 <0.001
Low 25.1 6.8
High 68.9 58.1
Abbreviations: OS overall survival, MST median survival time, mos months, HR hazard ratio, CI confidence interval
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MiR-29c reduces the capability of tumor cells to promote
HUVEC tube formation
To explore whether miR-29c-regulated VEGFA expression
is biological significant, HUVEC tube formation assays
were carried out using the TCM from LAD cells. HUVECs
were suspended in TCM and cultured on the matrigel
coated wells to form capillary tubes for 6 h. As shown in
Fig. 4, more mature, well-connected capillary tubes were
formed in the TCM derived from cells transfected with
miR-29c inhibitor. However, less well-organized capillary-
like structures were found for HUVECs in the TCM de-
rived from cells transfected with miR-29c mimic. Taken
Fig. 2 Effect of miR-29c on LAD cell proliferation, migration and invasion in vitro. a Expression levels of miR-29c in five LAD cells were analyzed
by qRT-PCR. b In the A549 cells, miR-29c was overexpressed by the miR-29c mimic. In the Anip973 cells, miR-29c was knocked down by the miR-29c
inhibitor. The miR-29c level was evaluated by qRT-PCR. c Cell proliferation abilities were determined in A549 cells with miR-29c overexpression and
Anip973 cells with miR-29c knockdown compared to those in NC transfected cells. d Cell migration and invasion abilities were determined in A549
cells with enforced miR-29c expression and Anip973 cells with reduced miR-29c expression compared to those in NC transfected cells.
*p < 0.05, **p < 0.01, and ***p < 0.001
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together, the above results suggest that miR-29c inhibits
the ability of tumor cells to promote HUVEC tube
formation.
MiR-29c regulates proliferation, migration, invasion and
angiogenesis through VEGFA
To investigate the role of VEGFA in proliferation, migra-
tion, invasion and angiogenesis of LAD cell, an expres-
sion construct carrying VEGFA ORF without 3’-UTR
was introduced into A549 cells for overexpression of
VEGFA. The compromised cell proliferation, migration,
invasion and angiogenesis induced by miR-29c mimic
transfection were almost completely reversed by trans-
fection of VEGFA expression plasmid (Fig. 5a-e). These
results suggest that miR-29c involves in regulation of cell
proliferation, migration, invasion and angiogenesis at
least partially depending on regulation of VEGFA.
Correlation of miR-29c with microvessel density and
VEGFA is valid in patients’ samples
To testify the correlations between miR-29c and MVD,
miR-29c and VEGFA expression in tumor tissues, IHC
of 20 FFPE specimens for CD31 (MVD) and VEGFA was
performed. As shown in Fig. 6, MVD and VEGFA ex-
pression correlated significantly with miR-29c expression
(p < 0.001).
Discussion
The biological functions of miRNAs in the progression
of lung cancer are becoming recognized [18] and there
is increasing interest in identifying the key miRNAs
involved in aggressive phenotypes of LAD to predict
clinical outcome and develop efficient therapeutic strate-
gies. In order to find prognosis related miRNA, we
performed miRNA microarray and identified miR-29c
expression to be an independent prognostic factor. We
Fig. 3 MiR-29c modulates LAD cells through targeting VEGFA. a The VEGFA 3’-UTR containing the wildtype or mutant miR-29c binding sequence
was inserted into downstream of the luciferase reporter vector. The mutated sequences are in italic. b The dual luciferase reporter assay revealed
that the luciferase activity controlled by VEGFA 3’-UTR was inhibited by ectopic miR-29c expression in A549 cells. ***p < 0.001. c VEGFA mRNA
levels determined by qRT-PCR following treatment of A549 cells with miR-29c mimic or Anip973 cells with miR-29c inhibitor. **p < 0.01. d ELISA
assay of secreted VEGFA protein levels in TCM after treatment of A549 cells with miR-29c mimic or Anip973 cells with miR-29c inhibitor. *p < 0.05,
**p < 0.01. e Western blot analyses of VEGFA protein levels following treatment of A549 cells with miR-29c mimic or Anip973 cells with miR-29c
inhibitor. β-actin was used as control
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found that there was no statistically significant association
between miR-29c expression and clinical characteristics.
Furthermore, expression of miR-29c was inversely corre-
lated with clinical outcome defined by OS, DFS, LRDFS
and DMFS. In addition, the prognostic role of miR-29c ex-
pression remained significant after adjusting for clinical
parameters in multivariable analysis. To our knowledge,
this is the first report to reveal that miR-29c may predict
clinical outcome in LAD.
MiR-29c is a member of miR-29 family which also in-
cludes miR-29a and miR-29b. MiR-29 family has been
observed to be aberrently expressed in different types of
cancer and be involved in biological functions including
cell proliferation, cell cycle, senescence, differentiation,
apoptosis and metastasis [19]. As for lung cancer, growing
evidence indicates that miR-29 family functions as tumor
suppressor and most studies focus on the biology of miR-
29b [8, 20–23]. However, despite the high similarity of
miR-29a/b/c mature sequence, studies have revealed that
different isoforms of miR-29 family may exert distinct
functions [24, 25]. Concerning the tumor suppressive role
of miR-29c in lung cancer, it has been demonstrated to re-
vert aberrant methylation by targeting DNA methyltrans-
ferases 3A and 3B and inhibit metastasis by targeting
integrin beta1 and matrix metalloproteinase 2 [20, 22]. As
introduced above, the biological function of miRNA
Fig. 4 MiR-29c reduces the capability of tumor cells to promote HUVEC tube formation. HUVECs were cultured in TCM derived from A549 cells
transfected with miR-29c mimic or mimic-NC and Anip973 cells transfected with miR-29c inhibitor or inhibitor-NC in 24-well matrigel coated
plates. a and b Representative images of tube formation and the relative number of tube branches measured in random 10 photographic fields
are presented. ***p < 0.001
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depends on cell types and LAD is a distinct subtype from
other histological types. To date, the role of miR-29c in
LAD has yet to be thoroughly elucidated.
It is well accepted that miRNAs perform their function
by regulating expression of multiple target genes. Bioinfor-
matics analysis revealed VEGFA may be the functional
target gene for miR-29c. We also found that miR-29c
directly bound with the 3’-UTR of VEGFA and suppressed
VEGFA expression. In addition, we showed that VEGFA
regulated by miR-29c was biologically active and influ-
enced HUVEC tube formation. Moreover, we observed
the suppression of proliferation, migtation/invasion and
angiongenesis by enforced miR-29c expression were al-
most completely rescued by overexpression of VEGFA in
Fig. 5 Forced expression of VEGFA abolishes the phenotype created by mimic transfection in A549 cells. a and b Cell migration and invasion
abilities were determined in A549 cells transfected with miR-29c mimic, mimic-NC and miR-29c mimic plus VEGFA expression plasmid. ***p < 0.001.
c Cell proliferation abilities were determined in A549 cells transfected with miR-29c mimic, mimic-NC and miR-29c mimic plus VEGFA expression
plasmid. *p < 0.05, **p < 0.01. d and e HUVECs were cultured in TCM derived from A549 cells transfected with miR-29c mimic, mimic-NC and miR-29c
mimic plus VEGFA expression plasmid. Representative images of tube formation and the relative number of tube branches measured in random 10
photographic fields are presented. **p < 0.01, ***p < 0.001
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A549 cells. The correlation of miR-29c with MVD and
VEGFA was further confirmed in patients’ samples. For
the first time, these results indicate that miR-29c modu-
lates proliferation, migration/invasion and angiogenesis by
targeting VEGFA in LAD. Since the miR-29 family mem-
bers share the same seed sequence, the target genes of
miR-29 family may be the same. MiR-29a and miR-29b
were reported to target VEGFA in gastric cancer and
breast cancer, respectively [26, 27]. The studies above fur-
ther supported our observations. However, unlike our
study, neither of the previous studies have performed an-
giogenic experiment in vitro nor in vivo to demonstrate
the anti-angiogenic role of miR-29.
Pathological angiogenesis is an established hallmark of
cancer which promotes tumor growth and metastasis
[28]. As a member of VEGF family, VEGFA is the most
potent proangiogenic factor. Clinical observations have
confirmed that VEGFA is frequently over-expressed in a
wide range of tumors and contributes to increased neo-
vascularization and poor prognosis [29]. Meta-analysis
revealed that expression of VEGFA is an unfavorable
prognostic factor in NSCLC [30]. Nowadays, VEGFA
antagonists such as bevacizumab have been used safely
in humans alone or in combination with chemotherapy
[31]. Bevacizumab, the monoclonal antibody against
VEGFA, has been proposed as first line treatment
combined with chemotherapy for advanced or metastatic
non-squamous NSCLC. The phase III trial Eastern
Cooperative Oncology Group (ECOG) 4599 demon-
strated prolongation of median overall survival by only
two months for the combination of bevacizumab and
paclitaxel/carboplatin followed by bevacizumab mainten-
ance compared to chemotherapy-alone [32]. Although
bevacizumab could offer an OS benefit, it should be
noted that the benefit is modest. Besides VEGFA, miR-
29c may target multiple genes and pathways to inhibit
tumor growth and metastasis [20, 22, 33–35], implicat-
ing miR-29c as a novel promising therapeutic target to
provide clinical benefit. The biological effects of VEGF
are mediated via binding to specific tyrosine kinase
receptors including VEGFR-1 and VEGFR-2. Based on
published data, NSCLC cell lines express VEGFR-2,
while VEGFR-1 protein is undetectable [36]. The study
suggests that miR-29c might modulate proliferation and
migration/invasion of lung adenocarcinoma cells by
VEGFR-2 which needs further investigation.
Conclusion
This study demonstrates that miR-29c plays a tumor-
suppressive role in LAD and its function is mainly medi-
ated by its target-VEGFA. These findings provide new
insight into the underlying mechanisms of LAD progres-
sion and highlight miR-29c as a potential prognostic
biomarker and therapeutic target of LAD.
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